T1	Participants 282 331	patients with progressive multiple sclerosis (MS)
T2	Participants 882 912	a single centre (Bristol, UK).
T3	Participants 913 1084	Eighty patients with progressive MS will be recruited; 60 will have secondary progressive disease (SPMS) but a subset (n = 20) will have primary progressive disease (PPMS)
T4	Participants 2306 2317	MS patients
